SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 18, 2022
(Exact name of registrant as specified in its charter)
|Minnesota|| ||0-7647|| ||41-0771293|
|(State of Incorporation)|| ||(Commission File Number)|| ||(IRS Employer Identification No.)|
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s Telephone Number, Including Area Code (612) 331-6910
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
Common Stock, par value $.01 per share
Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Exchange Act (17 CFR 240.12b 2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On May 18, 2022, Hawkins, Inc. issued a press release announcing financial results for its fourth quarter and fiscal year ended April 3, 2022. A copy of the press release issued by the Registrant is furnished herewith as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
|Exhibit No.|| ||Description|| ||Method of Filing|
Press Release, dated May 18, 2022, announcing financial results of Hawkins, Inc. for its fourth quarter and fiscal year ended April 3, 2022.
| ||Filed Electronically|
|104 ||Cover Page Interactive Data File (embedded within the inline XBRL document)||Filed Electronically|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ||HAWKINS, INC.|
Date: May 18, 2022
| ||By:|| ||/s/ Jeffrey P. Oldenkamp |
| || ||Jeffrey P. Oldenkamp |
| || |
Executive Vice President and Chief Financial Officer
|May 18, 2022|
|Roseville, MN 55113|
Hawkins, Inc. Reports
Fourth Quarter and Fiscal Year 2022 Results
ROSEVILLE, Minn., May 18, 2022 – Hawkins, Inc. (Nasdaq: HWKN), a leading specialty chemical and ingredients company, today announced fourth quarter and full-year results for its fiscal year ended April 3, 2022.
Fourth Quarter Fiscal Year 2022 Highlights:
•Record quarterly sales in the fourth quarter of $223.0 million, a 37% year-over-year increase.
•Gross profit of $36.3 million for the quarter, a 14% increase over the same period of the prior year, while absorbing $8.2 million in incremental LIFO expense in the quarter.
•Record fourth quarter diluted earnings per share (EPS) of $0.50, which was 16% higher than the same period of the prior year.
•Adjusted earnings before interest, taxes, depreciation, and amortization (adjusted EBITDA), a non-GAAP measure, of $22.3 million, an 11% increase over the same period of the prior year.
Full-Year Fiscal Year 2022 Highlights:
•Record annual sales of $774.5 million for fiscal 2022, a 30% year-over-year increase.
•Record gross profit of $146.5 million for the year, an 18% increase over the prior year, which contributed to a 27% year-over-year increase in operating income.
•Record diluted EPS of $2.44, which was $0.51, or 26%, higher than fiscal 2021.
•Record adjusted EBITDA, a non-GAAP measure, of $99.7 million, an increase of 19% over fiscal 2021.
•Full year net income increased 26% over the prior year.
•Paid cash dividends of $0.5225 per share for the year, representing an increase of 11% over the prior year. This marks the 37th consecutive year of paying a dividend.
•Completed three acquisitions during the year.
•Ended the year with net debt of $123 million and a leverage ratio of 1.25x.
•Issued our second annual ESG report, with a goal of being carbon neutral by 2040.
Executive Commentary – Patrick H. Hawkins, Chief Executive Officer and President:
“For the third year in a row we generated record operating income, net income, diluted EPS, and adjusted EBITDA, while achieving record sales of $775 million and adjusted EBITDA of $100 million in fiscal 2022. This strong three-year run has delivered compounded EPS growth of 29% over that timeframe. This performance is the result of the hard work by our many employees, our innovative solutions to the opportunities that have arisen, as well as outstanding relationships with our customers and suppliers, which we never take for granted. In fiscal 2022, we made significant investments in added personnel and other resources that we expect to leverage in the coming years to grow the business.”
Mr. Hawkins, continued, “We had 30% revenue growth for the year, which included the results of our six acquisitions over the past 18 months and a 27% organic growth from our existing business, with all three reporting segments growing over the prior year. Sales in our Industrial segment grew 42% over the prior year, with more than half of the year-over-year growth coming from our higher-margin business in agricultural, pharmaceutical and food ingredient product lines. Our margins continued to be impacted by macro-economic pressures, including inflation and global supply chain disruptions. Despite these headwinds, we generated $71 million of operating income, an increase of $15 million over the prior year and included a LIFO impact of nearly $16 million in fiscal 2022 due to unprecedented rising raw material costs. We look forward to continuing our topline growth into fiscal 2023 and managing our cost structure to drive our bottom line.”
Fourth Quarter and Fiscal Year Financial Highlights:
For the fourth quarter of fiscal 2022, the Company reported net income of $10.6 million, or $0.50 per diluted share, compared to net income for the fourth quarter of fiscal 2021 of $9.1 million, or $0.43 per diluted share.
For the full year, the Company reported record net income of $51.5 million, or $2.44 per diluted share, compared to net income for fiscal 2021 of $41.0 million, or $1.93 per diluted share.
For the fourth quarter of fiscal 2022, sales were $223.0 million, an increase of $60.0 million, or 37%, from sales of $163.0 million a year ago. Industrial segment sales increased $41.0 million, or 54%, to $117.4 million for the current quarter, as compared to $76.3 million for the same period a year ago. We estimate the impact of the extra week in the quarter to be approximately $10.0 million in additional sales in the Industrial segment. In addition, the increase in sales was driven by increased selling prices on many of our products driven by higher costs on many of our raw materials, as well as increased sales volumes of our bulk and our manufactured, blended and repackaged products. Water Treatment segment sales increased $18.5 million, or 45%, to $60.0 million for the current quarter, as compared to $41.5 million for the same period a year ago. We estimate the impact of the extra week in the quarter to be approximately $4.0 million in additional sales in the Water Treatment segment. In addition, sales increased as a result of increased demand for our products as well as the added sales from acquisitions. Health and Nutrition segment sales increased $0.4 million, or 1%, to $45.6 million for the current quarter, as compared to $45.2 million for the same period a year ago. We estimate the impact of the extra week in the quarter to be approximately $3.5 million in additional sales in the Health and Nutrition segment, which was partially offset by the normalizing of demand for our manufactured products when compared to the temporary COVID-driven increase in demand these products experienced in the prior year.
For fiscal 2022, Industrial segment sales were $386.9 million, an increase of 42% from fiscal 2021 sales of $273.4 million. Water Treatment segment sales were $228.1 million for the year, an increase of 34% over last year’s sales of $170.0 million. Sales for our Health and Nutrition segment were $159.5 million in fiscal 2022, an increase of 4% from fiscal 2021 sales of $153.5 million. We estimate the total impact of the extra week in the year to be approximately $17.5 million.
Company-wide gross profit for fiscal 2022 increased $22.8 million, or 18%, to $146.5 million, or 19% of sales, from $123.8 million, or 21% of sales, for the same period of the prior year. During fiscal 2022, the LIFO reserve increased, and gross profits decreased, by $15.8 million, primarily due to rising input costs. In fiscal 2021, the LIFO reserve decreased, and gross profits increased, by $0.1 million. We estimated the impact of the 53rd week in fiscal 2022 to be approximately $3.6 million in additional gross profit.
Gross profit for the Industrial segment increased $16.3 million, or 38%, to $59.6 million, or 15% of sales, for fiscal 2022, from $43.3 million, or 16% of sales, for fiscal 2021. During fiscal 2022, the LIFO reserve increased, and gross profits decreased, by $10.4 million, primarily due to rising raw material costs. In fiscal 2021, the LIFO reserve decreased, and gross profits increased, by $0.2 million. We estimated the impact of the 53rd week in fiscal 2022 to be approximately $1.9 million in additional gross profit in the Industrial segment. In addition, gross profit increased as a result of the increase in sales, partially offset by the negative impact as a result of the increase in LIFO reserve.
Gross profit for the Water Treatment segment increased $7.8 million, or 17%, to $54.6 million, or 24% of sales, for fiscal 2022, from $46.8 million, or 28% of sales, for fiscal 2021. During fiscal 2022, the LIFO reserve increased, and gross profits decreased, by $5.4 million, primarily due to rising raw material costs. During fiscal 2021, the LIFO reserve increased, and gross profit decreased, by $0.1 million. We estimated the impact of the 53rd week in fiscal 2022 to be approximately $1.0 million in additional gross profit in the Water Treatment segment. In addition, gross profit increased as a result of the increase in sales.
Gross profit for the Health and Nutrition segment decreased $1.3 million, or 4%, to $32.3 million, or 20% of sales, for fiscal 2022, from $33.6 million, or 22% of sales, for fiscal 2021. We estimated the impact of the 53rd week in fiscal 2022 to be approximately $0.7 million in additional gross profit in the Health and Nutrition segment. This increase was more than offset by a decrease in gross profit resulting from a decline in sales of our manufactured products which generally have higher per-unit margins than our specialty distributed products.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
Selling, general and administrative ("SG&A") expenses increased to $75.3 million, or 10% of sales, for fiscal 2022 from $67.9 million, or 11% of sales, for fiscal 2021. We estimated the impact of the 53rd week in fiscal 2022 to be approximately $1.0 million in additional SG&A expense. In addition, expenses increased in part due to the added costs from the acquired businesses in the Water Treatment segment, an increase in variable incentive compensation, increased costs due to added personnel and other resources as we invest to grow the business, and normalization of travel and other variable expenses to pre-COVID levels.
Adjusted EBITDA, a non-GAAP financial measure, is an important performance indicator and a key compliance measure under the terms of our credit agreement. An explanation of the computation of adjusted EBITDA is presented below. Adjusted EBITDA for the three months ended April 3, 2022 was $22.3 million, an increase of $2.2 million, or 11%, from adjusted EBITDA of $20.1 million for the same period in the prior year. Full-year adjusted EBITDA was $99.7 million, an increase of $15.8 million, or 19%, from adjusted EBITDA of $83.9 million for fiscal 2021. The increase was due to the impact of improved gross profits discussed above.
Our effective income tax rate was relatively flat at approximately 26.5% for both fiscal 2022 and 2021.
About Hawkins, Inc.
Hawkins, Inc. was founded in 1938 and is a leading specialty chemical and ingredients company that formulates, distributes, blends and manufactures products for its Industrial, Water Treatment, and Health & Nutrition customers. Headquartered in Roseville, Minnesota, and with 49 facilities in 24 states, the Company creates value for its customers through superb customer service and support, quality products and personalized applications. Hawkins, Inc. generated $775 million of revenue in fiscal 2022 and has approximately 800 employees. For more information, including registering to receive email alerts, please visit www.hawkinsinc.com/investors.
Reconciliation of Non-GAAP Financial Measures
We report our consolidated financial results in accordance with U.S. generally accepted accounting principles (GAAP). To assist investors in understanding our financial performance between periods, we have provided certain financial measures not computed according to GAAP, including adjusted EBITDA. This non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP measures. The method we use to produce non-GAAP results is not computed according to GAAP and may differ from the methods used by other companies.
Management uses this non-GAAP financial measure internally to understand, manage and evaluate our business and to make operating decisions. Management believes that this non-GAAP financial measure reflects an additional way of viewing aspects of our operations that, when viewed with our GAAP results, provides a more complete understanding of the factors and trends affecting our financial condition and results of operations.
We define adjusted EBITDA as GAAP net income adjusted for the impact of the following: net interest expense resulting from our net borrowing position; income tax expense; non-cash expenses including amortization of intangibles, depreciation, and charges for the employee stock purchase plan and restricted stock grants; and non-recurring items of income or expense, if applicable.
|Adjusted EBITDA||Three Months Ended||Fiscal Year Ended|
|(In thousands)||April 3, 2022||March 28, 2021||April 3, 2022||March 28, 2021|
|Net income (GAAP)||$||10,577 ||$||9,081 ||$||51,542 ||$||40,980 |
|Interest expense||409 ||366 ||1,404 ||1,467 |
|Income tax expense||3,864 ||3,586 ||18,437 ||14,871 |
|Amortization of intangibles||1,758 ||1,602 ||6,462 ||5,839 |
|Depreciation expense||4,512 ||4,331 ||17,667 ||16,829 |
|Non-cash compensation expense||1,111 ||1,040 ||3,818 ||3,343 |
|Non-recurring acquisition expense||73 ||54 ||369 ||562 |
|Adjusted EBITDA||$||22,304 ||$||20,060 ||$||99,699 ||$||83,891 |
CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(In thousands, except share and per-share data)
|Three Months Ended||Fiscal Year Ended|
| ||April 3, 2022||March 28, 2021||April 3, 2022||March 28, 2021|
|Sales||$||222,973 ||$||162,971 ||$||774,541 ||$||596,871 |
|Cost of sales||(186,654)||(131,221)||(628,021)||(473,109)|
|Gross profit||36,319 ||31,750 ||146,520 ||123,762 |
|Selling, general and administrative expenses||(21,110)||(18,875)||(75,326)||(67,884)|
|Operating income||15,209 ||12,875 ||71,194 ||55,878 |
|Interest expense, net||(409)||(366)||(1,404)||(1,467)|
|Other income (expense)||(359)||158 ||189 ||1,440 |
|Income before income taxes||14,441 ||12,667 ||69,979 ||55,851 |
|Income tax expense||(3,864)||(3,586)||(18,437)||(14,871)|
|Net income||$||10,577 ||$||9,081 ||$||51,542 ||$||40,980 |
|Weighted average number of shares outstanding-basic||20,887,460 ||20,968,248 ||20,947,234 ||21,024,344 |
|Weighted average number of shares outstanding-diluted||21,078,783 ||21,194,455 ||21,135,258 ||21,260,296 |
|Basic earnings per share||$||0.51 ||$||0.43 ||$||2.46 ||$||1.95 |
|Diluted earnings per share ||$||0.50 ||$||0.43 ||$||2.44 ||$||1.93 |
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share and per-share data)
|April 3, 2022||March 28, 2021|
|Cash and cash equivalents||$||3,496 ||$||2,998 |
|Trade accounts receivables, net||122,826 ||90,603 |
|Inventories||94,985 ||63,864 |
|Prepaid expenses and other current assets||6,431 ||5,542 |
|Total current assets||227,738 ||163,007 |
|PROPERTY, PLANT, AND EQUIPMENT:|
|Land||16,640 ||15,235 |
|Buildings and improvements||118,369 ||120,410 |
|Machinery and equipment||114,763 ||109,353 |
|Transportation equipment||43,968 ||37,646 |
|Office furniture and equipment||10,315 ||17,760 |
|304,055 ||300,404 |
|Less accumulated depreciation||142,209 ||155,792 |
|Net property, plant, and equipment||161,846 ||144,612 |
|Right-of-use assets||10,606 ||11,630 |
|Goodwill||77,401 ||70,720 |
|Intangible assets, net||80,193 ||76,368 |
|Deferred compensation plan asset||6,783 ||5,726 |
|Other||2,761 ||487 |
|Total other assets||177,744 ||164,931 |
|Total assets||$||567,328 ||$||472,550 |
|LIABILITIES AND SHAREHOLDERS’ EQUITY|
|Accounts payable — trade||$||66,693 ||$||37,313 |
|Accrued payroll and employee benefits||19,034 ||18,048 |
|Current portion of long-term debt||9,913 ||9,907 |
|Short-term lease liability||1,657 ||1,587 |
|Container deposits||1,558 ||1,452 |
|Other current liabilities||2,611 ||2,155 |
|Total current liabilities||101,466 ||70,462 |
|LONG-TERM DEBT, LESS CURRENT PORTION||115,644 ||88,845 |
|LONG-TERM LEASE LIABILITY||9,143 ||10,231 |
|PENSION WITHDRAWAL LIABILITY||4,276 ||4,631 |
|DEFERRED COMPENSATION LIABILITY||8,402 ||7,322 |
|DEFERRED INCOME TAXES||23,422 ||24,445 |
|OTHER LONG-TERM LIABILITIES||2,374 ||1,368 |
|Total liabilities||264,727 ||207,304 |
|COMMITMENTS AND CONTINGENCIES||— ||— |
|Common shares; authorized: 60,000,000 shares of $0.01 par value; 20,889,777 and 20,969,746 shares issued and outstanding for 2022 and 2021, respectively||209 ||210 |
|Additional paid-in capital||46,717 ||51,138 |
|Retained earnings||254,384 ||213,898 |
|Accumulated other comprehensive income||1,291 ||— |
|Total shareholders’ equity||302,601 ||265,246 |
|Total liabilities and shareholders’ equity||$||567,328 ||$||472,550 |
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
|Fiscal Year Ended|
| ||April 3, 2022||March 28, 2021|
|CASH FLOWS FROM OPERATING ACTIVITIES:|
|Net income||$||51,542 ||$||40,980 |
|Reconciliation to cash flows:|
|Depreciation and amortization||24,129 ||22,669 |
|Operating leases||1,899 ||1,896 |
|Gain on deferred compensation assets||(189)||(1,440)|
|Deferred income taxes||(1,501)||(689)|
|Stock compensation expense||3,818 ||3,343 |
|Other||545 ||203 |
|Changes in operating accounts (using) providing cash, net of acquisitions:|
|Accounts payable||25,138 ||2,551 |
|Accrued liabilities||2,723 ||7,554 |
|Income taxes||214 ||(235)|
|Net cash provided by operating activities||42,837 ||43,793 |
|CASH FLOWS FROM INVESTING ACTIVITIES:|
|Additions to property, plant, and equipment||(28,512)||(20,794)|
|Other||302 ||362 |
|Net cash used in investing activities||(49,756)||(71,432)|
|CASH FLOWS FROM FINANCING ACTIVITIES:|
|Cash dividends paid||(11,056)||(10,029)|
|New shares issued||1,772 ||1,583 |
|Shares surrendered for payroll taxes||(1,467)||(54)|
|Payments for debt issuance costs||(287)||— |
|Payments on senior secured revolving loan||(15,000)||(37,000)|
|Borrowings on senior secured revolving loan||42,000 ||76,000 |
|Net cash provided by financing activities||7,417 ||26,360 |
|NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS||498 ||(1,279)|
|CASH AND CASH EQUIVALENTS - beginning of year||2,998 ||4,277 |
|CASH AND CASH EQUIVALENTS - end of year||$||3,496 ||$||2,998 |
|SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION-|
|Cash paid during the year for income taxes||$||19,726 ||$||15,783 |
|Cash paid for interest||1,197 ||1,288 |
|Noncash investing activities - Capital expenditures in accounts payable||3,733 ||626 |
REPORTABLE SEGMENTS (UNAUDITED)
|Health and Nutrition||Total|
| || || |
|Fiscal Year Ended April 3, 2022:|
|Sales||$||386,938 ||$||228,133 ||$||159,470 ||$||774,541 |
|Gross profit||59,606 ||54,571 ||32,343 ||146,520 |
|Selling, general, and administrative expenses||28,127 ||31,357 ||15,842 ||75,326 |
|Operating income||31,479 ||23,214 ||16,501 ||71,194 |
|Fiscal Year Ended March 28, 2021:|
|Sales||$||273,361 ||$||170,004 ||$||153,506 ||$||596,871 |
|Gross profit||43,337 ||46,793 ||33,632 ||123,762 |
|Selling, general, and administrative expenses||27,033 ||24,453 ||16,398 ||67,884 |
|Operating income (loss)||16,304 ||22,340 ||17,234 ||55,878 |Forward-Looking Statements. Various remarks in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include those relating to consumer demand for products containing our ingredients and the impacts of those demands, expectations for results in our business segments and the timing of our filings with the Securities and Exchange Commission. These statements are not historical facts, but rather are based on our current expectations, estimates and projections, and our beliefs and assumptions. Forward-looking statements may be identified by terms, including “anticipate,” “believe,” “can,” “could,” “expect,” “intend,” “may,” “predict,” “should,” or “will” or the negative of these terms or other comparable terms. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. Actual results may vary materially from those contained in forward looking statements based on a number of factors, including, but not limited to, changes in regulation, availability of technological improvements, the impact and severity of the COVID-19 outbreak, changes in the labor markets, our available cash for investments, changes in competition and price pressures, changes in demand and customer requirements or processes for our products, availability of product and disruptions to supplies, interruptions in production resulting from hazards, transportation limitations or other extraordinary events outside our control that may negatively impact our business or the supply chains in which we participate, changes in imported products and tariff levels, the availability of products and the prices at which they are available, the acceptance of new products by our customers and the timing of any such acceptance, and changes in product supplies. Additional information concerning potential factors that could affect future financial results is included in our Annual Report on Form 10-K for the fiscal year ended March 28, 2021, as updated from time to time in amendments and subsequent reports filed with the SEC. Investors should take such risks into account when making investment decisions. Shareholders and other readers are cautioned not to place undue reliance on forward-looking statements, which reflect our management’s view only as of the date hereof. We do not undertake any obligation to update any forward-looking statements.
Contacts: Jeffrey P. Oldenkamp
Executive Vice President and Chief Financial Officer